Clinical Trial Update: Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL) [Phase 3]

View source ↗

Summary

Phase 3 trial update on efficacy and safety of Cevira in cervical HSIL (CIN2/3). Status not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Intraepithelial Neoplasia
• Cervical Intraepithelial Neoplasia 3

Drugs mentioned

• Cevira

Snippet

Sponsor: Asieris MediTech (Hong Kong) Co., Ltd. | Conditions: Cervical Intraepithelial Neoplasia Grade 2/3 | Phase 3 | Status: UNKNOWN